Eoneren
ImmunityBio (IBRX) on Saturday announced a licensing deal to acquire exclusive U.S. rights to a bladder cancer therapy called Bacillus Calmette-Guerin (BCG) treatment from Japan BCG Laboratory, a Japanese drug developer.
Under the agreement, the San Diego, California-based biotech will receive rights
